{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "CVS", "name": "CVS Health Corporation", "url": "https://frontierpicks.com/dossiers/CVS/", "json_url": "https://frontierpicks.com/dossiers/CVS.json", "status": "WATCHLIST", "current_conviction": "MEDIUM", "archetype": { "code": "a7", "n": 7 }, "current_thesis": "CVS Health is modestly more likely to beat the S&P 500 over three months: Aetna's costs improved and 2026 guidance rose, and the February 2027 report tests the 2027 outlook of at least $8.65 per share.", "invalidation_trigger": "A daily close below $81, under the $81.33 close of 2026-11-05 after the split announcement, which would show the rebound has failed; or a cut of the 2027 adjusted EPS outlook below $8.65 per share.", "catalyst_date": null, "portfolio": null, "pick": null, "themes": [ "managed-care-health-services", "m-and-a-special-situations" ], "tags": [], "sources": [], "notes": [ "CVS Health plans to split into two public companies, with completion expected in the first half of 2028; shareholders would own shares in both.", "After the split, the continuing CVS Health would hold Aetna, Caremark, specialty pharmacy, Oak Street Health and Signify Health; CVS Pharmacy would hold the stores, mail order, MinuteClinic and Health100." ], "source_links": [ { "title": "CVS HEALTH Corp - Form 8-K - FY2026", "url": "https://www.sec.gov/Archives/edgar/data/0000064803/000006480326000107/cvs_ex99x1q3-26.htm", "date": "2026-11-04" }, { "title": "Honolulu Star-Advertiser", "url": "https://www.staradvertiser.com/2026/11/04/breaking-news/cvs-shares-plunge-13-after-surprise-plan-to-split-company/", "date": "2026-11-04" }, { "title": "CVS Health CEO Pushes Back on $1 Billion Split Cost Estimate, Outlines Growth Plans", "url": "https://finance.yahoo.com/healthcare/articles/cvs-health-ceo-pushes-back-171504421.html", "date": "2026-11-09" }, { "title": "CVS Health Q3 2026 Earnings Call Transcript", "url": "https://www.benzinga.com/news/26/11/62864837/cvs-health-q3-2026-earnings-call-transcript", "date": null }, { "title": "CVS Health announces intent to create two distinct leaders in healthcare", "url": "https://www.cvshealth.com/news/company-news/cvs-health-announces-intent-to-create-two-distinct-leaders-in-healthcare.html", "date": null } ], "evidence": [ { "claim": "Third-quarter 2026 adjusted EPS was $2.09, up from $1.60 a year earlier; revenue was $108.4 billion, up 5.4%.", "source": "CVS Health 8-K exhibit 99.1, third-quarter 2026 results", "as_of": "2026-11-04" }, { "claim": "The medical benefit ratio improved to 91.3% from 92.8%, and Health Care Benefits adjusted operating income rose to $912 million from $314 million.", "source": "CVS Health 8-K exhibit 99.1, third-quarter 2026 results", "as_of": "2026-11-04" }, { "claim": "2026 adjusted EPS guidance raised to at least $8.20 from $7.90–8.10; operating cash flow guidance raised to at least $15.5 billion from at least $11.5 billion.", "source": "CVS Health 8-K exhibit 99.1, third-quarter 2026 results", "as_of": "2026-11-04" }, { "claim": "CVS Health guided 2027 adjusted EPS to at least $8.65, against an analyst estimate of $8.53, and announced a separation due in the first half of 2028; the shares fell about 13% that session.", "source": "Reuters via Honolulu Star-Advertiser", "as_of": "2026-11-04" }, { "claim": "Chief Executive David Joyner said recurring dis-synergies from the split are closer to $500 million than the more than $1 billion some investors estimated.", "source": "Wolfe Research healthcare conference remarks, reported by MarketBeat", "as_of": "2026-11-09" }, { "claim": "EVP and Group President Prem S. Shah bought 23,855 shares on the open market at $83.89.", "source": "SEC Form 4", "as_of": "2026-11-06" }, { "claim": "AM Best placed the credit ratings of Aetna Life Insurance Company and other Aetna Health & Life Group members under review with developing implications.", "source": "AM Best announcement", "as_of": "2026-11-06" }, { "claim": "Wells Fargo lowered its CVS Health price target to $112; Goldman Sachs lowered its target to $115 from $120 on 2026-11-06.", "source": "Wells Fargo and Goldman Sachs analyst notes", "as_of": "2026-11-12" } ], "view_changes": [], "frame": null, "filed_numbers": { "as_of": "2026-11-13", "sector": "Healthcare", "financials": { "status": "ok", "reason": null, "close_date": "2026-11-13", "latest_quarter": "2026-09-30", "figures": { "revenue": { "status": "ok", "quarters": [ { "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 108399, "yoy_pct": 5.4 }, { "end": "2026-06-30", "filed": "2026-08-05", "value_musd": 106096, "yoy_pct": 7.3 }, { "end": "2026-03-31", "filed": "2026-05-06", "value_musd": 100426, "yoy_pct": 6.2 }, { "end": "2025-12-31", "filed": "2026-02-10", "value_musd": 105693, "yoy_pct": 8.2 }, { "end": "2025-09-30", "filed": "2026-11-04", "value_musd": 102871, "yoy_pct": 7.8 }, { "end": "2025-06-30", "filed": "2026-08-05", "value_musd": 98915, "yoy_pct": 8.4 } ] }, "gross_margin": { "status": "ok", "quarters": [ { "end": "2026-09-30", "filed": "2026-11-04", "pct": 43.6 }, { "end": "2026-06-30", "filed": "2026-08-05", "pct": 44.5 }, { "end": "2026-03-31", "filed": "2026-05-06", "pct": 44.8 }, { "end": "2025-12-31", "filed": "2026-02-10", "pct": 44.1 }, { "end": "2025-09-30", "filed": "2026-11-04", "pct": 44.5 }, { "end": "2025-06-30", "filed": "2026-08-05", "pct": 45.4 } ] }, "operating_margin": { "status": "ok", "quarters": [ { "end": "2026-09-30", "filed": "2026-11-04", "pct": 3.3 }, { "end": "2026-06-30", "filed": "2026-08-05", "pct": 4.4 }, { "end": "2026-03-31", "filed": "2026-05-06", "pct": 4.7 }, { "end": "2025-12-31", "filed": "2026-02-10", "pct": 2 }, { "end": "2025-09-30", "filed": "2026-11-04", "pct": -3.1 }, { "end": "2025-06-30", "filed": "2026-08-05", "pct": 2.4 } ] }, "pretax_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 2849 }, "net_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "four_quarters_end": "2026-09-30", "value_musd": 2172, "four_quarters_musd": 11037 }, "operating_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "first_end": "2025-12-31", "value_musd": 18708 }, "capital_spending": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "first_end": "2025-12-31", "value_musd": 3141 }, "free_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "first_end": "2025-12-31", "value_musd": 15567 }, "diluted_share_change": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "base_end": "2025-09-30", "pct": 1.7 }, "cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 14887 }, "debt": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 60680, "composition": "non-current long-term debt and finance leases plus current maturities" }, "net_cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": -45793 }, "deferred_revenue": { "status": "ok", "end": "2025-12-31", "filed": "2026-02-10", "value_musd": 62, "yoy_pct": -56.9 }, "backlog": { "status": "not reported" }, "receivables": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 42073 }, "inventory": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 18240 }, "equity": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 80497 }, "market_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-28", "basis_filed": "2026-11-04", "value_musd": 114321 }, "enterprise_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-28", "basis_filed": "2026-11-04", "value_musd": 160114 }, "ev_sales": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-28", "basis_filed": "2026-11-04", "multiple": 0.4 }, "ev_ebit": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-28", "basis_filed": "2026-11-04", "multiple": 10.6 }, "pe": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-28", "basis_filed": "2026-11-04", "multiple": 10.4 }, "pb": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-28", "basis_filed": "2026-11-04", "multiple": 1.4 }, "fcf_yield": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-28", "basis_filed": "2026-11-04", "pct": 13.6 } } }, "short_interest": { "status": "ok", "settlement": "2026-10-15", "published": "2026-11-13", "short_pct_of_outstanding": 1.27, "days_to_cover": 1.6, "change_pct": -1.7 }, "insiders": { "status": "ok", "as_of": "2026-11-14", "windows": [ { "days": 90, "status": "ok", "from": "2026-08-17", "bought_usd": 2001315.22, "sold_usd": 0, "bought_unpriced": 0, "sold_unpriced": 0 }, { "days": 365, "status": "ok", "from": "2025-11-15", "bought_usd": 2001315.22, "sold_usd": 323709755.23, "bought_unpriced": 0, "sold_unpriced": 0 } ] } }, "body_markdown": "## Current Thesis\nCVS Health is modestly more likely to beat the S&P 500 over the next three months than to lag it. Aetna's medical costs are improving, the company raised its 2026 guidance, and the selloff after the 2026-11-04 split announcement left the shares below the level those results support. The fourth-quarter report, expected in early February 2027, settles it. That report shows whether the 2027 outlook of at least $8.65 in adjusted earnings per share holds.\n\nThe third quarter was strong. The company's 8-K results exhibit dated 2026-11-04 shows adjusted EPS of $2.09, against $1.60 a year earlier and an LSEG analyst average of $1.65, as reported by Reuters. The medical benefit ratio improved to 91.3% from 92.8%. The 2026 adjusted EPS guide rose to at least $8.20, from $7.90–8.10. On the same day, the company announced a tax-free separation into two public companies, due in the first half of 2028. The shares fell about 13% that session, according to Reuters.\n\nThe market is pricing a pause in 2027 earnings plus separation costs. The shares closed at $89.79 on 2026-11-12. That is 18.9% below the 52-week intraday high of $110.68 set on 2026-07-22, even after the guidance raise. The rating is Medium. Results and insider buying support the shares, but the separation adds costs and cash-flow questions that will not be settled before 2028.\n\n## Bull Case\n- **Health insurance margins are recovering.** Health Care Benefits adjusted operating income rose to $912 million in the third quarter of 2026, from $314 million a year earlier, according to the 2026-11-04 results exhibit. Total revenue was $108.4 billion, up 5.4%.\n- **Cash guidance rose sharply.** The 2026 operating cash flow guide rose to at least $15.5 billion, from at least $11.5 billion (results exhibit, 2026-11-04). On the earnings call that day, management said share repurchases resume in the fourth quarter because the company reached its leverage target ahead of schedule.\n- **Management sized split costs below outside estimates.** At the Wolfe Research conference on 2026-11-09, Chief Executive David Joyner said recurring costs of running two companies are closer to $500 million than the more than $1 billion some investors had estimated. One-time costs come on top. He put deployable capital across the two businesses at about $35 billion, per MarketBeat.\n- **The future pharmacy chief bought shares.** Prem S. Shah will lead CVS Pharmacy after the split. He bought 23,855 shares on the open market at $83.89 on 2026-11-06, according to his SEC Form 4.\n- **The retail pharmacy outlook improved.** Management said at the 2026-11-09 conference that the pharmacy business is now expected to grow at a low single-digit rate. It had earlier planned for a 5% decline. Management expects 2027 to be the third straight year of higher adjusted operating income in that business.\n\n## Bear Case\n- **2027 is a trough year for earnings.** Management called 2027 a trough year for the continuing CVS Health because of rebate guarantees and the 340B drug pricing program, per MarketBeat on 2026-11-09. On 2026-11-04, Kevin Gade of Bahl & Gaynor called the 2027 outlook \"an earnings hiccup\" next to peers whose growth is speeding up, per Reuters.\n- **Membership and selling conditions are softening.** On 2026-11-04, Chief Financial Officer Brian Newman flagged softer selling conditions and declining health plan membership for 2027, according to Reuters.\n- **Analysts cut targets after the report.** Every target cut still sits above the 2026-11-12 close. Goldman Sachs cut its target to $115 from $120 on 2026-11-06. UBS cut to $107, also on 2026-11-06. Leerink Partners cut to $104 on 2026-11-05, Argus to $105 from $114 on 2026-11-10, and Wells Fargo to $112 on 2026-11-12.\n- **Credit and regulatory overhangs.** On 2026-11-06, AM Best placed the ratings of Aetna Life Insurance Company and related units under review with developing implications. On 2026-11-04, UBS analyst Kevin Caliendo called the split \"a defensive move against regulation,\" per Reuters.\n- **Little financial detail on the split yet.** Barclays analyst Andrew Mok named the lack of financial detail on the breakup as investors' main concern on 2026-11-04, per Reuters.\n\n## Setup & Price Structure\nThe shares closed at $81.33 on 2026-11-05, the session after the split announcement. They recovered to $89.79 by 2026-11-12. That close sits above the 50-day moving average of $89.38 and the 200-day moving average of $88.01, both as of 2026-11-12 from adjusted daily closes. The 3-month price change is −6.9%, measured from the 2026-08-14 close.\n\nThe levels that matter are on both sides. Below is the 2026-11-05 close of $81.33, the low point after the announcement. Above is the 52-week intraday high of $110.68 from 2026-07-22. The 52-week closing low was $70.08 on 2026-03-27. A close back under both moving averages would show that the post-announcement recovery is fading.\n\n## Catalyst Calendar\n\n- **~2027-02-10 (est.):** Fourth-quarter 2026 results and 2027 guidance update. This report shows whether the 2027 adjusted EPS outlook of at least $8.65 per share holds and whether the medical cost improvement continued into the fourth quarter.\n- **~2027-02 (est.):** Medicare Advantage enrollment update for 2027. Management deferred the enrollment update to February; a bigger membership decline than flagged would add to the 2027 trough-year pressure.\n\n## What Would Change Our Mind\n\nA daily close below $81, under the $81.33 close of 2026-11-05 after the split announcement, which would show the rebound has failed; or a cut of the 2027 adjusted EPS outlook below $8.65 per share.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Medical cost trends rise again and reverse the improvement in Aetna's medical benefit ratio. Confirmed by: A fourth-quarter 2026 medical benefit ratio above the year-earlier level, or managed-care peers reporting higher cost trends in their fourth-quarter results.\n- Rebate guarantees and the 340B drug pricing program pressure 2027 earnings at Caremark more than guided. Confirmed by: Management lowering the 2027 adjusted EPS outlook of at least $8.65, or citing larger pharmacy-benefit headwinds at the fourth-quarter report.\n- Separation costs and dis-synergies come in above management's estimate of about $500 million a year. Confirmed by: Separation filings or management guidance putting recurring standalone costs well above $500 million, or large one-time costs that cut cash flow guidance.\n- AM Best's review leads to a downgrade of Aetna insurance subsidiaries. Confirmed by: AM Best concluding its review with a downgrade or a negative outlook on Aetna Life Insurance Company.\n- Regulatory action against pharmacy-benefit managers that own retail pharmacies. Confirmed by: New state or federal legislation forcing changes to Caremark's ownership or contracts before the 2028 separation.\n\n## Correlation Notes\nCVS Health trades mostly with large managed-care insurers, because Aetna's medical cost ratio drives the swings in earnings. Cost-trend comments from peers move the shares, as do Medicare Advantage enrollment updates; management said on 2026-11-09 that its next enrollment update comes in February. The Caremark benefits manager and the retail pharmacies add exposure to drug-pricing and pharmacy-benefit regulation that pure insurers do not carry.", "first_seen": "2026-11-12", "last_analyzed": "2026-11-13T03:47:50+00:00", "last_synthesized": "2026-11-13", "date_modified": "2026-11-13", "license": "Content © FrontierPicks. Cite the canonical URL." }